• Revenue up 38% to $600,659
• Loss down 99.7% to $16,434
• Shift from CBD to THC flower products
• Executing DOCA with Biortica Agrimed

Bod Science Limited (subject to a Deed of Company Arrangement) reported a 38% increase in revenue to $600,659 and a 99.7% decrease in loss to $16,434 for the half-year ended 31 December 2024. The company's sales revenue from its MedicaBilis and Bod Flora medicinal cannabis products in Australia and the UK increased by 140% to $600,659. This was driven by the launch of the company's first THC product in December 2023 and the launch of a further eight THC products since. The company has shifted its focus from selling predominantly CBD products to predominantly THC flower products. Non-CBD, over the counter, legacy health and beauty products had no sales during the half-year due to the company's exit from this business early in the prior financial year. Other income for the half-year was $799,237, including $591,446 in funding income from Biortica. The company's gross profit margin was 34% compared to 36% in the prior half-year. Discretionary costs decreased due to the company being subject to a DOCA, with research and development down 99%, marketing expense down 97%, and other expenses down 86%. In November 2024, the company executed a binding conditional Share Purchase Agreement with the Biortica ordinary shareholders to acquire all the fully paid ordinary shares in Biortica, in consideration for the issue of ordinary shares in the company. The DOCA will be effectuated once the conditions subsequent to the DOCA are satisfied, which is expected to occur on or before 30 September 2025.